Company intelligence / Profile preview
Mission Therapeutics
Cambridge, Cambridgeshire, United Kingdommissiontherapeutics.com ↗
- Ownership
- Private
- Employees
- ~11-50
- Development stage
- Other
01
Overview
Mission Therapeutics has received FDA approval to initiate Phase II clinical trial of MTX652 in Acute Kidney Injury and MHRA Clinical Trial Authorization for MTX325 for Parkinson's Disease. The company is developing first-in-class small molecule DUB inhibitors.
- Therapeutic areas
- CardiovascularNephrologyOtherOncologyRare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Mission Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mission Therapeutics.